ClinicalTrials.gg

Program

GUB014295

A development code.

In AbbVie's pipeline, Long-Acting Amylin Analog. Its studies are mostly in Overweight, led by AbbVie.

Furthest: phase 1, since Nov 8, 20231 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie10 open or runningphase 1since Nov 8, 2023Nov 8, 2023none ahead
  • Named in AbbVie’s own pipeline as ABBV-295, phase 2, as of Jul 30, 2026 (source).

Also a collaborator on its studies: quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 8, 2023First study: phase 1 study in OverweightFirst studyNCT06144684 · 76 enrolled · United Kingdom

TargetBeta

“Long-Acting Amylin Analog”the company's pipeline, read by Claude · source

Other programs on CALCR

ProgramCompanyFurthest phaseStudies
cagrilintideNovo Nordiskphase 350
zenagamtideNovo Nordiskphase 335
petrelintideruleZealand Pharmaphase 311
ABBV-295AbbViephase 25
PF-08653945Pfizerphase 22
CagriSema ANovo Nordiskphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06144684Overweight · United Kingdom1CompletedJan 5, 202676

How it is read

Names in the registry

  • “GUB014295”, 1 entry

Codes read as this program: GUB014295.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.